Analyst Price Target is $4.67
▲ +43.15% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Xeris Biopharma in the last 3 months. The average price target is $4.67, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 43.15% upside from the last price of $3.26.
Current Consensus is
Buy
The current consensus among 3 polled investment analysts is to buy stock in Xeris Biopharma. This Buy consensus rating has held steady for over two years.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Read More